Cutis marmorata telangiectatica congenita

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1556OMIM:219250Q82.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Cutis marmorata telangiectatica congenita (CMTC), also known as congenital generalized phlebectasia or Van Lohuizen syndrome, is a rare congenital vascular disorder characterized by a persistent, pronounced marbled (reticular) pattern of the skin caused by dilated surface blood vessels. Unlike the common and benign cutis marmorata (a temporary mottling of the skin seen in many newborns in response to cold), CMTC is present at birth and persists, often with a more striking, fixed, dark blue or purple reticular pattern. The condition primarily affects the skin but can involve multiple body systems. The hallmark feature is a localized or generalized reticulated (net-like) vascular pattern on the skin, which may be accompanied by skin atrophy, ulceration, and telangiectasias (small dilated blood vessels). The affected skin areas may appear thinner than normal. CMTC can be associated with asymmetry of the limbs (one limb being larger or smaller than the other), body asymmetry, and occasionally with other congenital anomalies including glaucoma, other eye abnormalities, syndactyly, and other vascular malformations. In some cases, it may overlap with or be part of broader vascular malformation syndromes such as macrocephaly-capillary malformation syndrome (M-CM syndrome). In many patients, the skin findings tend to improve gradually during the first few years of life, though they may not resolve completely. There is no specific cure for CMTC. Treatment is primarily supportive and symptomatic, focusing on monitoring and managing associated complications. Regular ophthalmologic examinations are recommended to screen for glaucoma, and orthopedic follow-up may be needed if limb asymmetry is present. Dermatologic monitoring is important for skin ulceration. Laser therapy has been used in some cases to address persistent telangiectasias. The overall prognosis is generally favorable, particularly in isolated cases without significant associated anomalies.

Also known as:

Clinical phenotype terms— hover any for plain English:

LeukocoriaHP:0000555Subcutaneous hemorrhageHP:0001933
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Cutis marmorata telangiectatica congenita.

View clinical trials →

No actively recruiting trials found for Cutis marmorata telangiectatica congenita at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Cutis marmorata telangiectatica congenita community →

No specialists are currently listed for Cutis marmorata telangiectatica congenita.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Cutis marmorata telangiectatica congenita.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Cutis marmorata telangiectatica congenitaForum →

No community posts yet. Be the first to share your experience with Cutis marmorata telangiectatica congenita.

Start the conversation →

Latest news about Cutis marmorata telangiectatica congenita

No recent news articles for Cutis marmorata telangiectatica congenita.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Cutis marmorata telangiectatica congenita

What is Cutis marmorata telangiectatica congenita?

Cutis marmorata telangiectatica congenita (CMTC), also known as congenital generalized phlebectasia or Van Lohuizen syndrome, is a rare congenital vascular disorder characterized by a persistent, pronounced marbled (reticular) pattern of the skin caused by dilated surface blood vessels. Unlike the common and benign cutis marmorata (a temporary mottling of the skin seen in many newborns in response to cold), CMTC is present at birth and persists, often with a more striking, fixed, dark blue or purple reticular pattern. The condition primarily affects the skin but can involve multiple body syste

How is Cutis marmorata telangiectatica congenita inherited?

Cutis marmorata telangiectatica congenita follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Cutis marmorata telangiectatica congenita typically begin?

Typical onset of Cutis marmorata telangiectatica congenita is neonatal. Age of onset can vary across affected individuals.